Geron offers 157% upside to the analyst consensus price target with 31% revenue growth and two recent earnings beats, but the company falls below the minimum investable market cap at $0.74 billion, burns cash at 47% of revenue, and carries a put-to-call ratio of 5.00 — the asymmetry is extraordinary on paper, yet the business is too small and too speculative to meet the investability threshold.
Thesis pillars
- Extraordinary Upside Asymmetry→Stable
- Below Minimum Investable Threshold→Stable
- Cash Burn Limits Runway→Stable
- +1 more pillar — see the Why tab for full reasoning
Geron Corporation (GERN) Stock Analysis
Recovery setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $1.36: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10 and A.R:R 7.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality; Negative price momentum.
Geron Corporation is a commercial-stage biopharmaceutical company that markets RYTELO (imetelstat), a first-in-class telomerase inhibitor FDA-approved in June 2024 for transfusion-dependent anemia in lower-risk myelodysplastic syndromes, with EU approval following in March 2025.... Read more
Sell if holding. Engine safety override at $1.36: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10 and A.R:R 7.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality; Negative price momentum. Chart setup: Death cross but MACD improving, RSI 74. Score 6.0/10, moderate confidence.
Passes 6/9 gates (favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 33d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.
About Geron Corporation
About Geron Corporation
Geron Corporation's only FDA-approved product, RYTELO (imetelstat) -- a first-in-class telomerase inhibitor -- won approval in June 2024 for transfusion-dependent anemia in lower-risk myelodysplastic syndromes and has been sold in the U.S. since mid-2024. The European Commission approved RYTELO for the same lower-risk MDS population in March 2025, covering all 27 EU member states plus Iceland, Norway, and Liechtenstein, with a planned 2026 EU launch through third-party commercialization partners rather than Geron's own sales force.
Geron generates revenue almost entirely from U.S. sales of RYTELO, distributed through a select network of third-party distributors and specialty pharmacies rather than direct-to-patient sales, supported by a commercial organization of more than 60 key account managers and regional directors plus the REACH4RYTELO patient-support program. Outside the U.S., Geron does not plan to commercialize RYTELO independently; it has partnered with Tanner Pharma for named patient program access ahead of a planned 2026 launch in select EU markets, though revenue from those programs has been minimal to date. Beyond the approved lower-risk MDS indication, Geron is running the Phase 3 IMpactMF trial testing imetelstat in relapsed/refractory myelofibrosis, which completed enrollment in September 2025; the company expects an interim overall-survival analysis in the second half of 2026 and a final analysis in the second half of 2028.
Show full overview
Geron's near-term financial trajectory is a single-product story: the 10-K states RYTELO is the company's only FDA-approved product and that its ability to generate meaningful revenue and reach profitability is wholly dependent on RYTELO's continued U.S. commercial uptake. That makes the pending Phase 3 IMpactMF readout in relapsed/refractory myelofibrosis a binary catalyst for diversifying the revenue base -- a positive result and label expansion would extend RYTELO into a second indication, while a negative outcome would leave Geron dependent on lower-risk MDS penetration alone, a population the company itself describes as having relatively low incidence and prevalence.
See also: Healthcare · Biotechnology
From Geron Corporation's most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-06Recent Developments — Geron Corporation
Latest news
- NEWS Geron To Present Real-World Moffitt Cancer Center Study Showing RYTELO (imetelstat) Safety And Efficacy In Lower-Risk MD — benzinga May 12, 2026
- NEWS Earnings Scheduled For May 6, 2026 — benzinga May 6, 2026
- NEWS Geron Reports Q1 2026 Results: Full Earnings Call Transcript — benzinga May 6, 2026 neutral
- NEWS Geron Expects FY26 RYTELO Net Product Revenue $220M-$240M; Sees Total Operating Expenses $230M-$240M — benzinga May 6, 2026 neutral
- NEWS Geron Q1 EPS $(0.01) Beats $(0.02) Estimate, Sales $51.771M Beat $50.582M Estimate — benzinga May 6, 2026 positive
Generated 2026-07-06T06:00:34Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductRYTELO (imetelstat)10-K Item 1A: 'RYTELO is our only product approved for marketing by the FDA, and our ability to generate meaningful revenue from product sales and achieve profitability is wholly dependent on our ability to successfully commercialize RYTELO'
Material Events(8-K, last 90d)
- 2026-05-27Item 5.02LOWStockholders approved an amendment to Geron's 2018 Equity Incentive Plan at the May 20, 2026 annual meeting, increasing shares issuable under the plan by 4,500,000, as previously adopted by the Board subject to stockholder approval.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $1.36: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10 and A.R:R 7.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality; Negative price momentum. Chart setup: Death cross but MACD improving, RSI 74. Prior stop was $1.26. Score 6.0/10, moderate confidence.
Take-profit target: $2.96 (+117.6% upside). Prior stop was $1.26. Stop-loss: $1.26.
Concentration risk — Product: RYTELO (imetelstat); Quality below floor (3.1 < 4.0).
Geron Corporation trades at a P/E of N/A (forward 20.9). TrendMatrix value score: 8.0/10. Verdict: Sell.
12 analysts cover GERN with a consensus score of 4.0/5. Average price target: $3.
What does Geron Corporation do?Geron Corporation is a commercial-stage biopharmaceutical company that markets RYTELO (imetelstat), a first-in-class...
Geron Corporation is a commercial-stage biopharmaceutical company that markets RYTELO (imetelstat), a first-in-class telomerase inhibitor FDA-approved in June 2024 for transfusion-dependent anemia in lower-risk myelodysplastic syndromes, with EU approval following in March 2025. RYTELO is Geron's only FDA-approved product, and the company's revenue and profitability depend entirely on its continued U.S. commercial uptake.